---
title: "Xolair (omalizumab), all indications: Safety questions"
description: "Safety questions on Xolair (omalizumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings and Side effects. Questions: Can Xolair cause anaphylaxis (boxed warning)? When does anaphylaxis happen after a Xolair dose? Who is at higher risk of anaphylaxis with Xolair? What are the contraindications for Xolair? 5 further questions follow. 9 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xolair/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab), all indications: Safety questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)  
Indication pages: [Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)

## Warnings

<a id="xolair-boxed-warning"></a>

### Can Xolair cause anaphylaxis (boxed warning)?

> “WARNING: Anaphylaxis”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=WARNING%3A%20Anaphylaxis)

> “Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Because of the risk of anaphylaxis, initiate XOLAIR therapy in a healthcare setting and closely observe patients for an appropriate period of time after XOLAIR administration. Health care providers administering XOLAIR should be prepared to manage anaphylaxis which can be life-threatening. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should symptoms occur. Selection of patients for self-administration of XOLAIR should be based on criteria to mitigate risk from anaphylaxis.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Anaphylaxis%20presenting%20as%20bronchospasm%2C%20hypotension%2C,to%20mitigate%20risk%20from%20anaphylaxis.)

<a id="xolair-anaphylaxis-timing"></a>

### When does anaphylaxis happen after a Xolair dose?

> “In premarketing clinical trials in patients with asthma, anaphylaxis was reported in 3 of 3507 (0.1%) patients. Anaphylaxis occurred with the first dose of XOLAIR in two patients and with the fourth dose in one patient. The time to onset of anaphylaxis was 90 minutes after administration in two patients and 2 hours after administration in one patient.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=In%20premarketing%20clinical%20trials%20in,after%20administration%20in%20one%20patient.)

> “Approximately 60% to 70% of anaphylaxis cases have been reported to occur within the first three doses of XOLAIR, with additional cases occurring sporadically beyond the third dose.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Approximately%2060%25%20to%2070%25%20of,sporadically%20beyond%20the%20third%20dose.)

> “There have been reports of anaphylaxis occurring up to 4 days after administration of 
> XOLAIR”

Source: [XOLAIR: Prescribing information, page 43, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=43)

<a id="xolair-anaphylaxis-risk-factors"></a>

### Who is at higher risk of anaphylaxis with Xolair?

> “A case-control study in asthma patients showed that, among XOLAIR users, patients with a history of anaphylaxis to foods, medications, or other causes were at increased risk of anaphylaxis associated with XOLAIR, compared to those with no prior history of anaphylaxis.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=A%20case%2Dcontrol%20study%20in%20asthma,no%20prior%20history%20of%20anaphylaxis.)

> “The study found 
> that a self-reported history of anaphylaxis to foods, medications or other causes was more 
> common among patients with XOLAIR anaphylaxis (57% of 30 cases) compared to controls 
> (23% of 88 controls) [OR 8.1, 95% CI 2.7 to 24.3].”

Source: [XOLAIR: Prescribing information, page 17, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=17)

<a id="xolair-contraindications"></a>

### What are the contraindications for Xolair?

> “XOLAIR is contraindicated in patients with a severe hypersensitivity reaction to XOLAIR or to any ingredient of XOLAIR.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=XOLAIR%20is%20contraindicated%20in%20patients,to%20any%20ingredient%20of%20XOLAIR.)

> “Discontinue XOLAIR in patients who experience a severe hypersensitivity reaction.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Discontinue%20XOLAIR%20in%20patients%20who%20experience%20a%20severe%20hypersensitivity%20reaction.)

<a id="xolair-serum-sickness"></a>

### Can Xolair cause fever, joint pain, and rash (serum sickness)?

> “Fever, Arthralgia, and Rash: In post-approval use, some patients have experienced a constellation of signs and symptoms, including arthritis/arthralgia, rash, fever, and lymphadenopathy with an onset 1 to 5 days after the first or subsequent injections of XOLAIR. These signs and symptoms have recurred after additional doses in some patients. Physicians should stop XOLAIR if a patient develops this constellation of signs and symptoms.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Fever%2C%20Arthralgia%2C%20and%20Rash%3A%20In,constellation%20of%20signs%20and%20symptoms.)

<a id="xolair-parasitic-infection"></a>

### Does Xolair increase the risk of parasitic worm infections?

> “Parasitic (Helminth) Infection: Monitor patients at high risk of geohelminth infection while on XOLAIR therapy. Insufficient data are available to determine the length of monitoring required for geohelminth infections after stopping XOLAIR treatment.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Parasitic%20%28Helminth%29%20Infection%3A%20Monitor%20patients,infections%20after%20stopping%20XOLAIR%20treatment.)

> “In a one-year clinical trial conducted in Brazil in adult and adolescent patients at high risk for 
> geohelminthic infections (roundworm, hookworm, whipworm, threadworm), 53% (36/68) of 
> XOLAIR-treated patients experienced an infection, as diagnosed by standard stool 
> examination, compared to 42% (29/69) of placebo controls.  The point estimate of the odds 
> ratio for infection was 1.96, with a 95% confidence interval (0.88, 4.36) indicating that in this 
> study a patient who had an infection was anywhere from 0.88 to 4.36 times as likely to have 
> received XOLAIR than a patient who did not have an infection.  Response to appropriate 
> anti-geohelminth treatment of infection as measured by stool egg counts was not different 
> between treatment groups.”

Source: [XOLAIR: Prescribing information, page 15, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=15)

<a id="xolair-emergency-use"></a>

### Can Xolair be used as an emergency treatment for allergic reactions?

> “Potential Medication Error Related to Emergency Treatment of Anaphylaxis: XOLAIR should not be used for the emergency treatment of allergic reactions, including anaphylaxis. In studies to simulate use, some patients and caregivers did not understand that XOLAIR is not intended for the emergency treatment of allergic reactions, including anaphylaxis. The safety and effectiveness of XOLAIR for emergency treatment of allergic reactions, including anaphylaxis, have not been established.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=Potential%20Medication%20Error%20Related%20to,anaphylaxis%2C%20have%20not%20been%20established.)

## Side effects

<a id="xolair-hair-loss"></a>

### Can Xolair cause hair loss?

> “The following adverse reactions have been identified during postapproval use of XOLAIR.  
> Because these reactions are reported voluntarily from a population of uncertain size, it is not 
> always possible to reliably estimate their frequency or establish a causal relationship to drug 
> exposure.”

Source: [XOLAIR: Prescribing information, page 22, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=22)

> “Skin: Hair loss has been reported.”

Source: [XOLAIR: Prescribing information, page 23, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=23)

## Safety

<a id="xolair-report-side-effects"></a>

### How do I report Xolair side effects?

> “You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682.”

Source: [XOLAIR: Important Safety Information | XOLAIR® (omalizumab) | HCP, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/side-effects/important-safety-information.html#:~:text=You%20may%20report%20side%20effects,Pharmaceuticals%20Corporation%20at%20%28888%29%20669%2D6682.)

## Related pages
- [Medical information: Xolair (omalizumab): All indications](https://www.evicenter.com/medical-information/xolair)
- [Indication](https://www.evicenter.com/medical-information/xolair/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/xolair/pharmacology)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/xolair/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair/access-and-coverage)
